The pentameric or hexameric architecture of IgM in principle allows for higher avidity due to multivalent antigen binding and an enhanced ability to activate the complement system, making it highly promising for cancer immunotherapy (5) (6) (7),,. The gene discussed is CD40LG; the disease is cancer.